03:31 PM EST, 12/15/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that Enhertu, in combination with pertuzumab, has been approved in the US as a first-line treatment for adult patients with unresectable or metastatic HER2 positive breast cancer.

The approval has been based on Destiny-Breast09 phase 3 study results that showed Enhertu in combination with pertuzumab reduced the risk of disease progression by 44% versus taxane, trastuzumab and pertuzumab, AstraZeneca ( AZN ) said.

Enhertu is an antibody drug conjugate discovered by Daiichi Sankyo and is being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca ( AZN ), the company said.

Shares of AstraZeneca ( AZN ) were up nearly 2% in recent Monday trading.

Price: 91.54, Change: +1.71, Percent Change: +1.90